The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

9 articles for E Nanba


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Fluorinated Chaperone-ß-Cyclodextrin Formulations forß-Glucocerebrosidase Activity Enhancement in Neuronopathic Gaucher Disease.EBI
University of Sevilla
Inhibitor versus chaperone behaviour of d-fagomine, DAB and LAB sp(2)-iminosugar conjugates against glycosidases: A structure-activity relationship study in Gaucher fibroblasts.EBI
University of Seville
Efficient stereoselective synthesis of 2-acetamido-1,2-dideoxyallonojirimycin (DAJNAc) and sp(2)-iminosugar conjugates: Novel hexosaminidase inhibitors with discrimination capabilities between the mature and precursor forms of the enzyme.EBI
The Barcelona Institute of Science and Technology
Conformationally-locked N-glycosides: exploiting long-range non-glycone interactions in the design of pharmacological chaperones for Gaucher disease.EBI
Universitat Rovira I Virgili
Conformationally-locked N-glycosides with selectiveß-glucosidase inhibitory activity: identification of a new non-iminosugar-type pharmacological chaperone for Gaucher disease.EBI
Universitat Rovira I Virgili
Synthesis of new camptothecin analogs with improved antitumor activities.EBI
Chugai Pharmaceutical
Pharmacological Chaperones for the Treatment of α-Mannosidosis.EBI
University of Sevilla
Disubstituted azepan orexin receptor antagonistsBDB
Merck Sharp & Dohme